Introduction
============

Nonsyndromic complete or incomplete cleft of the lip and palate is one of the most frequent congenital defects occurring in humans. The incidence of this malformation is influenced by ethnic origin, genetics and by environmental factors ([@b1-ijmm-40-05-1323]). This malformation bears the burden of serious medical, aesthetic and psychosocial consequences. Notably, a genetic link between this disorder and risk of cancer in the affected person has been identified ([@b2-ijmm-40-05-1323]). Clinical studies have demonstrated that an early surgical repair of the cleft lip results in the most favourable outcome. The cleft should be reconstructed as soon as possible, preferably during the first postnatal week. This strategy appears to be successful in terms of improved healing, as well as minimized scar formation ([@b3-ijmm-40-05-1323]--[@b5-ijmm-40-05-1323]). However, even this very early timing of cheiloplasty is unable to fully prevent future growth irregularities typical of this malformation ([@b6-ijmm-40-05-1323],[@b7-ijmm-40-05-1323]). The excellent results of early cheiloplasty are not surprising, as the prenatal period (the first two trimesters) is associated with the fully regenerative type of healing. Fetal healing in the last trimester of pregnancy, as well as early postnatal healing, is also notably rapid and associated with minimal scar formation ([@b8-ijmm-40-05-1323],[@b9-ijmm-40-05-1323]). This marked difference between prenatal/neonatal and adult types of wound healing was widely evaluated, and explained by reduced readiness of fetuses and neonates to development of inflammation. Interleukin-10 (IL-10) inhibiting the immune response is considered the principal cytokine regulating immune response of this stage ([@b10-ijmm-40-05-1323]--[@b13-ijmm-40-05-1323]).

However, the underlying mechanism of the hypertrophic form of scarring remains unclear with the majority of research focusing on the pro-fibrotic growth factor, transforming growth factor-β1 (TGF-β1). TGF-β signaling is complex and context dependent. The TGF-β family of growth factors is involved in numerous processes in wound healing: Inflammation, angiogenesis stimulation, fibroblast proliferation, collagen synthesis, and deposition and remodelling of the new extracellular matrix. It has been suggested that three known isoforms of TGF-β (−1, −2 and −3) exert different temporal effects on wound healing and scarring, and any disruption in their expression pattern may result in hypertrophic scar formation ([@b14-ijmm-40-05-1323]). Fibroblasts from hypertrophic scars indeed demonstrated increased TGF-β1 expression levels; however, they were also demonstrated to exhibit prolonged expression of the TGF-β receptors compared with normal skin, thus enhancing downstream signaling and target gene activation ([@b15-ijmm-40-05-1323]). Interestingly, animals lacking SMAD family member (Smad)3, a principal component of the signaling cascade, demonstrated improved wound-healing (achieved by the increased rate of re-epithelization and reduced infiltration of monocytes) ([@b16-ijmm-40-05-1323]).

Scarless wound healing is also associated with a reduction of the production of growth factors, which influence fibroblasts and keratinocytes ([@b17-ijmm-40-05-1323]), and with changes in extracellular matrix remodelling ([@b18-ijmm-40-05-1323]). Fetal keratinocytes differ from their adult counterparts structurally and functionally ([@b19-ijmm-40-05-1323]). Suspensions of keratinocytes prepared from neonatal epidermis contain a pool of very small keratinocytes (diameter, 4 *µ*m) that express vimentin ([@b20-ijmm-40-05-1323]). This size determinant is a classical marker of clone-forming ability in human keratinocytes ([@b21-ijmm-40-05-1323]). These cells appear to be morphologically similar to very small stem cells ([@b22-ijmm-40-05-1323]). The ability of small keratinocytes isolated from the neonates to re-epithelise the experimental defect in the confluent culture of epithelial cells improves *in vitro* when compared with keratinocytes prepared from adult donors ([@b23-ijmm-40-05-1323]).

The neonatal fibroblasts are highly active and influence diverse cells in their environment. Notably, adult keratinocytes acquire properties of neonatal keratinocytes, including the occurrence of very small ones under their influence ([@b23-ijmm-40-05-1323]). This result is supported by the observation that the neonatal fibroblasts, as well as their products, exert a distinct anti-fibrotic effect ([@b19-ijmm-40-05-1323],[@b24-ijmm-40-05-1323]). This broad activity is to be expected, as fibroblasts are drivers of the embryonic development of epidermal appendages. Under conditions of normal development, fibroblasts determine what the newly formed appendage structure will be, such as hair, tooth, scale or feather ([@b25-ijmm-40-05-1323]). Under pathological conditions, cancer-associated fibroblasts are drivers of the aggressiveness of squamous epithelium-originated cancer. The crosstalk between epithelial cells and fibroblasts over the course of wound healing and in cancer are quite similar ([@b26-ijmm-40-05-1323],[@b27-ijmm-40-05-1323]).

In the present study, the differences between neonatal cleft lip fibroblasts (NCF) and older child cleft lip fibroblasts (OCCF) were investigated, with emphasis on the cleft lip repair strategy and prognosis. Our previous results ([@b20-ijmm-40-05-1323],[@b23-ijmm-40-05-1323]) demonstrated a high expression level of nestin, a marker of immature cells, and paradoxically also the presence of smooth muscle actin (SMA), a marker of terminally differentiated cells, in neonatal fibroblasts. Thus, a detailed analysis of the expression levels of nestin and SMA was performed in neonates. In addition, the neonatal dermal fibroblasts were further investigated with a focus on possible overlap with a molecular signature typical for neural crest-originated hair follicle stem cells ([@b20-ijmm-40-05-1323]). This aspect seems to be developmentally relevant, with respect to the origin of (ecto-) mesenchymal cells from the neural crest in the head region. These data include analysis of expression profiles of neonatal, child, and adult fibroblasts as well as the fibroblasts harvested from scars.

Materials and methods
=====================

Isolation of cells and cell culture
-----------------------------------

Dermal fibroblasts were isolated from residual skin during cleft lip reconstructive surgery as follows: Neonates (age, 1--16 days), 24 samples; older children (age, 3 months-6 years), 8 samples; control samples of adults (age, 23--77 years), 8 samples (4 from the breast and 4 from the face); scars from the trunk of adult patients (age, 38 and 78 years), 2 samples. The skin samples were acquired at the Ear, Nose and Throat (ENT) Department of the University Hospital in Motol and from the Department of Plastic Surgery, University Hospital Královské Vinohrady (Prague, Czech Republic). The samples of the scars were obtained from the Department of Dermatovenerology, General University Hospital (Prague, Czech Republic). All samples were collected under Local Ethics Committee approval in accordance with the ethical standards of the Institutional and National Research Committee, and according to the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The informed consent was obtained from all individual participants, or their legal representatives in the case of minors, included in the present study. Certain samples were cryoprotected using Tissue-Tek (Sakura Finetek Europe B.V., Zoeterwoude, The Netherlands) and frozen in liquid nitrogen. The 10 *µ*m sections were prepared using CryoCut (Reichert-Jung, Viena, Austria) and were used for immunohistochemistry. The processing of skin samples for cell cultivation and the isolation of fibroblast populations were described in detail by Krejčí *et al* ([@b20-ijmm-40-05-1323]). Residual skin samples were cut to very small sections (up to 1 mm^3^) which were shortly digested in 0.25% trypsin (Sigma-Aldrich, Prague, Czech Republic) for 20 min at 37°C and then transferred into CellBIND 6-well plates (Corning, Schiphold Rijk, The Netherlands). Skin explants were cultured in minimal volume of Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with antibiotics (penicillin 10 U/ml and streptomycin 100 *µ*g/ml) 10% of fetal bovine serum (FBS) (all from Biochrom, Berlin, Germany) and 100 *µ*g/ml gentamycin (Sigma-Aldrich) at 37°C and 5% CO~2~ in humidified incubator. Fibroblasts emigrated from tissue samples were harvested by 1:1 v/v mixtures of 0.25% trypsin and 0.02% ethylenediaminetetraacetic acid (EDTA; Biochrom, Berlin, Germany). Isolated fibroblasts were characterized by their negativity for leukocyte marker, cluster of differentiation (CD)45, melanocyte markers (melanoma antigen A and HMB-45), keratins, and positivity for vimentin. The absence of bacterial contamination was continuously controlled by visualization under a microscope. The absence of mycoplasma was verified by staining with 4′,6-diamidino-2-phenylindole (DAPI; Merck KGaA, Darmstadt, Germany). Routinely, all fibroblast populations were cultured in DMEM supplemented with antibiotics (penicillin 10 U/ml and streptomycin 100 *µ*g/ml) and 10% FBS at 37°C and 5% CO~2~ in a humidified incubator.

Immunocytochemistry
-------------------

Fibroblasts were inoculated at a density of 1,500 cells/cm^2^ on the coverslips, placed in 8-well dishes (Nunc; Thermo Fisher Scientific, Inc., Waltham, Ma, USA) and cultured in DMEM for 4 days (for nestin, octamerbinding transcription factor 4 and Nanog) or to full confluence (generally 7 day for SMA). The culture medium was refreshed every two days.

Fibroblasts that were adherent to coverslips were fixed by 5% (w/v) paraformaldehyde in phosphate-buffered saline (PBS; pH 7.2), washed three times with PBS and permeabilized with 0.05% Triton X-100 (Sigma-Aldrich; Merck KGaA). The non-specific binding of immunoglobulins via Fc receptors was blocked by 3.3% non-immune porcine serum (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA). The employed antibodies are presented in [Table I](#tI-ijmm-40-05-1323){ref-type="table"} (antibody dilutions were according to the supplier\'s instructions). The specificity of the immunocytochemical reaction was evaluated by use of isotype controls or irrelevant antibodies rather than specific antibodies. The cell nuclei were counterstained with DAPI. The specimens were mounted in Vectashield (Vector Laboratories, Ltd., Peterborough, UK) and analyzed using an Eclipse 90i fluorescence microscope (Nikon Corp., Tokyo, Japan) equipped with a ProgRes MF Cool camera (Jenoptik Optical Systems GmbH, Jena, Germany) and NIS-Elements AR4.40.00 computer-assisted image analysis system (Laboratory Imaging, Prague, Czech Republic).

Western blot analysis
---------------------

The cells of each fibroblast population were seeded at a density of 1,000 cells/cm^2^ into 10-cm diameter Petri dishes (Corning, Inc., Corning, NY, USA) and cultured for 7 days (95--100% confluence). The culture medium was refreshed every two days. The cell lysates were harvested according to the standard protocol in NP-40 cell lysis buffer (Thermo Fisher Scientific, Inc.). The supernatant was collected into a fresh microtube containing Protease Inhibitor Cocktail (Sigma-Aldrich; Merck KGaA). The total protein concentration was detected using the Bradford method for protein quantitation ([@b28-ijmm-40-05-1323]). Samples were resolved by 1-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels according to standard techniques. Equal quantities of total protein (10 *µ*g) were subjected to 12% SDS-PAGE (electrophoresis for 60 min, 100 V, in cold room at 4°C) and transferred onto polyvinylidene difluoride membranes. The membranes were subsequently blocked with 5% goat serum (Sigma-Aldrich) for 1 h and probed with specific SMA primary antibody (dilution, 1:1,000; overnight at 4°C), followed by the appropriate horseradish peroxidase-conjugated secondary antibody (dilution, 1:5,000; 60 min at room temperature). Proteins were detected using the KPL TrueBlue blotting detection reagents (BioVendor Laboratory Medicine, Inc., Brno, Czech Republic).

Detection of IL-6, IL-8 and TGF-β1 by enzyme-linked immunosorbent assay (ELISA)
-------------------------------------------------------------------------------

The cells of each fibroblast population were seeded at a density of 30,000 cells/cm^2^ into two wells (two technical replicates) of a 6-well plate (TPP Techno Plastic Products AG, Trasadingen, Switzerland). The next day, the culture medium was removed and 2.5 ml fresh DMEM was placed in each well. After 24 h, the conditioned medium was collected (each replicate separately), filtered through a 0.2-*µ*m microstrainer to remove the floating cells, divided into 500-*µ*l aliquots and stored at −20°C. Using Human IL-8, IL-6 and TGF-β1 kits (cat. nos. El1008-1, El1006-1 and ET3102-1; BioVendor Laboratory Medicine Inc.), the concentration of the proteins was detected according to the producer\'s instructions. The final intensity of yellow coloration was measured at a wavelength of 450 nm using a Universal Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT, USA).

Cell proliferation assay and TGF-β treatment/inhibition
-------------------------------------------------------

Fibroblasts from different donors \[neonates with cleft lip with (n=2) or without (n=2) family history; children, n=2; adult facial (n=2)/breast (n=2) fibroblasts\] were seeded at a density of 750 cells/well in 96-well plates. To achieve full adherence, cells were incubated at 37°C overnight in DMEM with 10% FBS. The next day, the culture medium was changed to media containing following active substances. TGF-β signaling blockade was performed selectively using small drug inhibitor SB-431542 (Sigma-Aldrich) at a concentration of 10 *µ*mol/l, which completely abrogates phosphorylation of SMAD2 in fibroblasts ([@b29-ijmm-40-05-1323]). The control cells were maintained in DMEM plus 10% FBS. Recombinant human TGF-β1, TGF-β2 and TGF-β3 (all Sigma-Aldrich) were dissolved in 4 mM HCl with 0.1% of bovine serum albumin at a concentration 10 ng/*µ*l and, for the experiments, they were used at a final concentration of 10 ng/ml DMEM. Cell proliferation was continuously monitored using an IncuCyte ZOOM Kinetic live cell imaging system (Essen BioScience, Ann Arbor, MI, USA) and measured as the phase object confluence percentage. All experiments were performed in triplicate and monitored for one week. Graphs were plotted and aligned (at 15% confluence) in the R statistical environment. The growth of cells was compared after 96 h, where the growth curves were in the log phase.

Microarray analysis
-------------------

The cells of each fibroblast population were seeded at a density of 1,000 cells/cm^2^ into two 6-cm diameter Petri dishes (Corning, Inc.) and cultured for 7 days (95--100% confluence). The culture medium was changed every two days and 24 h before harvest. The cells were washed twice with Dulbecco\'s PBS (Biochrom GmbH, Berlin, Germany), and 350 *µ*l buffer RLT (Qiagen GmbH, Hilden, Germany) and 2-mercaptoethanol (Sigma-Aldrich; Merck KGaA) was added. Using automatic pipette, the cell lysates (two technical replicates of each population) were collected into small Eppendorf tubes, immediately frozen and stored at −80°C.

Total RNA was isolated using an RNeasy micro kit (cat. no. 74004; Qiagen, Inc., Valencia, CA, USA) according to the procedure for animal cells. The quantity of RNA was measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.). The quality of the RNA was analyzed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.). The RNA samples with an RNA integrity number \>9 were used for further analysis.

Illumina HumanHT-12 v4 chips (Illumina, Inc., San Diego, CA, USA) were used for the microarray analysis according to the standard protocol. Total RNA (150 ng) was amplified using an Illumina TotalPrep RNA amplification kit (cat. no. AMIL1791; Ambion; Thermo Fisher Scientific, Inc.), and 0.75 *µ*g of the amplified RNA was hybridized on the chips according to the manufacturer\'s protocol. The analysis was performed in three biological replicates for the adult scar fibroblast group, nine biological (plus three technical) replicates for the adult breast fibroblast group, five biological replicates for the adult facial fibroblast group, seven biological (plus six technical) replicates for the OCCF group, and 24 biological (plus 18 technical) replicates for the NCF group.

The raw data was preprocessed using GenomeStudio software (version 1.9.0.24624; Illumina, Inc.) and further analyzed using the oligo ([@b30-ijmm-40-05-1323]) and limma ([@b31-ijmm-40-05-1323]) packages of the bioconductor ([@b32-ijmm-40-05-1323]) within the R environment ([@b33-ijmm-40-05-1323]). Briefly, the transcription profiles were background corrected using a normal-exponential model, quantile normalized and variance stabilized using base 2 logarithmic transformation. A moderated t-test was used to detect differentially expressed transcripts (after fitting a linear model I\~group \* gender within limma). A Storey\'s q-value of \<0.1 ([@b34-ijmm-40-05-1323]) and a minimum of a 2-fold change in expression intensity were required to consider genes as differentially transcribed. The Minimum Information About a Microarray Experiment compliant data was deposited to the ArrayExpress database (accession no. E-MTAB-5385).

Gene set enrichment analysis (GSEA) was performed using Fisher\'s exact test on gene sets defined by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways ([@b35-ijmm-40-05-1323]) and the terms of the Gene Ontology (GO) ([@b36-ijmm-40-05-1323]). The gene sets were compared with the set of differentially expressed genes in the respective comparisons. Only the KEGG pathways (resp. GO terms) with GSEA p\<0.005, a minimal overlap of six genes, and odds ratio \>3 (resp. five) were considered to be statistically significant.

Statistical analysis
--------------------

Statistical analysis was performed using Paleontological Statistics (version 3.14; University of Oslo, Oslo, Norway) and the nonparametric Kruskal-Wallis test (by ranks) was performed for pairwise comparisons. p\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Nestin and SMA are expressed by neonatal fibroblasts
----------------------------------------------------

While almost all NCF isolates exhibited distinct signals for nestin, the signal in the OCCF group was strongly reduced and the number of nestin-positive cells in the samples from normal adult face or breast tissue was negligible ([Fig. 1A--C](#f1-ijmm-40-05-1323){ref-type="fig"}). Similar profiles were observed in the transcriptomics data ([Fig. 1D](#f1-ijmm-40-05-1323){ref-type="fig"}) and confirmed in the sections of the human dermis ([Fig. 2](#f2-ijmm-40-05-1323){ref-type="fig"}). The high incidence of fibroblasts expressing nestin in NCF populations corresponded well with the presence of cells with nuclei that were positive for pluripotency markers, Oct4 and Nanog ([Fig. 3A--C](#f3-ijmm-40-05-1323){ref-type="fig"}). This was observed in cultures with or without SMA exhibiting myofibroblasts. No obvious correlation of *nestin*, *Nanog homeobox* and *POU* class *5 homeobox 1* was detected in transcriptomic data ([Fig. 3D and E](#f3-ijmm-40-05-1323){ref-type="fig"}). In comparison to the fibroblasts isolated from normal adult breast and face tissue samples, the NCF and OCCF groups often exhibited signals for SMA, as detected by immunocytochemistry ([Fig. 4A and B](#f4-ijmm-40-05-1323){ref-type="fig"}). However, the expression level of this protein was even stronger, as western blot analyses of NCF lysates exhibited SMA even in the populations that were morphologically negative for the presence of SMA in its typical fibrillary pattern (also termed stress fibres) as detected by immunofluorescence ([Fig. 4C](#f4-ijmm-40-05-1323){ref-type="fig"}). Overall, 50% of NCF and OCCF samples exhibited signals for fibrillar SMA ([Fig. 4D](#f4-ijmm-40-05-1323){ref-type="fig"}). The transcriptomic activity of actin α2, smooth muscle, aorta, the gene coding for SMA, was also elevated in the NCF and OCCF groups when compared with adult cells, predominantly from the face ([Fig. 4E](#f4-ijmm-40-05-1323){ref-type="fig"}). In addition, the NCF and OCCF groups expressed a greater quantity of actin γ2, smooth muscle, enteric when compared with adult breast or scar fibroblast samples ([Fig. 4F](#f4-ijmm-40-05-1323){ref-type="fig"}).

Expression levels of IL-6 and IL-8 differ between fibroblast groups
-------------------------------------------------------------------

As it is known that the transition of fibroblasts to SMA-positive myofibroblasts is strongly stimulated by TGF-β1 ([@b37-ijmm-40-05-1323]), this cytokine was measured by ELISA in the media conditioned by all of the investigated fibroblasts. No significant differences between the NCF and OCCF groups, as well as the adult fibroblasts were identified in the expression level of TGF-β1 (data not shown). IL-6, IL-8 and C-X-C motif chemokine ligand-1 (CXCL-1) are produced by fibroblasts during the course of wound healing, as well as by cancer-associated fibroblasts and they influence the low differentiation status of normal human keratinocytes ([@b38-ijmm-40-05-1323]). Production of IL-6 by NCF was significantly higher than by adult fibroblasts ([Fig. 5A](#f5-ijmm-40-05-1323){ref-type="fig"}). No difference in production of IL-8 among the investigated cell types was observed ([Fig. 5C](#f5-ijmm-40-05-1323){ref-type="fig"}). In the case of CXCL-1, none of the evaluated fibroblast types produced detectable quantities of this chemokine to the medium (data not shown). At the transcript level, NCF and, in particular, OCCF transcribed the *IL-6* gene more than the adult breast fibroblasts \[3-fold upregulated; (p\<0.05) ([Fig. 5B](#f5-ijmm-40-05-1323){ref-type="fig"})\]. By contrast, the *IL-8* gene was expressed to a lesser extent in the NCF and OCCF groups when compared with in adult breast fibroblasts \[threefold downregulated; (p\<0.05, resp. p=0.06) ([Fig. 5D](#f5-ijmm-40-05-1323){ref-type="fig"})\]. No change in CXCL1 expression was detected.

Transcription profiling reveals the involvement of TGF-β signaling
------------------------------------------------------------------

NCF group differed from adult cells isolated from the face in transcription activity of hundreds of genes. Similar differences were identified between the OCCF group and fibroblasts prepared from adult face skin, and in comparison of NCF and OCCF groups, respectively, to the fibroblasts isolated from the chest ([Fig. 6](#f6-ijmm-40-05-1323){ref-type="fig"}; supplementary data, <https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5385/>). While the changes between the NCF and OCCF groups, and adult breast cells were dominated by the changes in signaling pathways, the differences between the NCF and OCCF groups, and adult facial fibroblasts were dominated by the changes in metabolic pathways (<https://www.ebi.ac.uk/array-express/experiments/E-MTAB-5385/>). This fact reflects the common ontological origin of the facial cells (NCF, OCCF and adult facial fibroblasts), which differs from the adult breast fibroblast. It is widely accepted that facial mesenchyme is originated from the neural crest (termed ectomesenchyme) and so it differs, concerning its origin, from fibroblasts in other parts of the body ([@b25-ijmm-40-05-1323]). The transcriptomic analysis indeed demonstrated a difference between fibroblasts prepared from the face and breast in 364 genes (<https://www.ebi.ac.uk/array-express/experiments/E-MTAB-5385/>). The differentially expressed genes included members of the homeobox gene family ([Fig. 7](#f7-ijmm-40-05-1323){ref-type="fig"}) ([@b39-ijmm-40-05-1323]). Their expression intensity was independent of the disease/cleft status.

Among the most dysregulated KEGG pathways, which distinguished the adult samples and neonate/child samples were advanced glycation endproducts-receptor for advanced glycation endproducts (AGE-RAGE) signaling (hsa04933), TGF-β signaling (hsa04350) and TNF signaling pathway (hsa04668). Closer analysis of the AGE-RAGE signaling pathway revealed that the changes in this pathway accumulate in its TGF-β module (TGF-β2, TGF-β3 and TGF-βR2) ([Fig. 8](#f8-ijmm-40-05-1323){ref-type="fig"}) and inflammation-associated modules (IL-8, matrix metalloproteinase-2 and vascular endothelial growth factor A). Thus, there was significant enrichment of differentially expressed genes involved in TGF-β signaling. These findings were supported by the GSEA analysis on the GO terms. In the comparison of adult facial fibroblasts to nCF, pronounced changes were observed in the term, GO:0071604, *TGF-β* production, with large changes in transcription of the genes CD2 associated protein (*CD2AP*), CD34 molecule (*CD34*), hypoxia inducible factor 1α subunit (*HIF1A*), CD24 molecule (*CD24*), prostaglandin-endoperoxide synthase 2 (*PTGS2*) and MET proto-oncogene, receptor tyrosine kinase (*MET*). Additionally, GO term analysis revealed shared changes in the expression of genes involved in skeletal development, mesenchyme proliferation and microtubule polymerization. Adult breast fibroblasts differed from the neonatal and child facial fibroblasts in the expression of genes connected to chemotaxis and organ development, including heart morphogenesis and neural crest development, (<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5385/>). The latter of the above-mentioned changes were also observed in the comparison of adult breast and facial fibroblasts. This was expected for the neural crest genes; however, the observation of changes in organs (for example, heart development) were not anticipated. The largest contribution to detection of heart development by GSEA had the heart and neural crest derivatives expressed 2 (Hand2) gene, a transcription factor involved in the development of various organs. Notably, the Hand2 gene was associated with cleft palate in mice ([@b40-ijmm-40-05-1323]). No significant dysregulation of the GO terms associated with TNF signaling was observed, which may have been caused by a lack of statistical strength. TGF-β signaling, however, reoccurred in the GSEA analyses on the GO terms and KEGG pathways; therefore, this pathway became the study focus ([Fig. 9](#f9-ijmm-40-05-1323){ref-type="fig"}).

Virtually no differences between the transcription of genes in NCF and OCCF were observed
-----------------------------------------------------------------------------------------

The NCFs significantly differed from fibroblasts prepared from scar located on the body in 994 genes and a similar difference (807 genes) was observed during the comparison of OCCFs and adult scar fibroblasts ([Fig. 6](#f6-ijmm-40-05-1323){ref-type="fig"}). The GSEA analysis results were similar to the comparison of the adult fibroblasts to NCF and OCCF, with a notable exception of the p53 signaling pathway and apoptosis (sestrin 1, *cyclin dependent kinase inhibitor 2A* and *phorbol-12-myristate-13-acetate-induced protein 1*). Finally, only subtle differences between NCF and OCCF were observed: only two genes were significantly different between these fibroblasts and only one of them was protein-coding (*structural maintenance of chromosomes 6*).

Differences in sensibility to TGF-β inhibition
----------------------------------------------

TGF-β signaling was determined as the most likely difference between adult and child fibroblasts. Furthermore, a high incidence of myofibroblasts was observed in cultures of NCFs and OCCFs, which supported the decision to focus the study on the TGF family. No differences in the expression level of TGF-β1 were observed; however, the activity of TGF-β2, TGF-β3, and receptor TGF-βR2 in the NCF and OCCF groups appears to be functionally relevant ([Fig. 8A--C](#f8-ijmm-40-05-1323){ref-type="fig"}). In NCFs and OCCFs, the activity of the *SMAD3* gene, a product of which is downstream of the TGF-β signaling cascade, supported this finding ([Fig. 8E](#f8-ijmm-40-05-1323){ref-type="fig"}). Certain differences between adult fibroblasts obtained from breast and facial samples were observed, namely in the case of TGF-β3 and TGF-α ([Fig. 8B and D](#f8-ijmm-40-05-1323){ref-type="fig"}). In addition, changes in the transcriptional activity of the genes that likely regulate TGF-β signaling (*CD2AP*, *CD34*, *HIF1A*, *CD24*, *PTGS2* and *MET*) were observed. The role of TGF-β3 and inhibitor of TGF-β signaling in the growth of NCFs and OCCFs, and adult fibroblasts was also analyzed. The results demonstrated that TGF-β3 exerted no influence on the cell culture growth; however, the adult cells and OCCF were sensitive to TGF-β receptor inhibition. NCF were insensitive in this case ([Fig. 10](#f10-ijmm-40-05-1323){ref-type="fig"}).

Discussion
==========

The observation that NCF and OCCF strongly express SMA, and are therefore regarded as myofibroblasts, represents the main finding of the present study. Myofibroblasts frequently originate as a result of the transition of local fibroblasts in various locations. This transition appears to be triggered by an excess of TGF-β ([@b37-ijmm-40-05-1323],[@b41-ijmm-40-05-1323],[@b42-ijmm-40-05-1323]). Myofibroblasts also represent the common element of tumour stroma, and positively influence tumour growth and spread. Furthermore, similar cells are present in granulation tissue of the wound and influence the process of healing, including wound contraction ([@b27-ijmm-40-05-1323]). The observations at mRNA level from the present study demonstrate dysregulation of TGF-β signaling with upregulation of transcripts for TGF-β2 and TGF-β3, and downregulation of receptor, TGF-βR2. Etiopathogenesis of the orofacial cleft is associated with aberrant TGF-β signaling ([@b43-ijmm-40-05-1323]--[@b45-ijmm-40-05-1323]). In addition, TGF-β appears to influence the phenotype of fibroblasts isolated from cleft palate ([@b46-ijmm-40-05-1323]). Low production of IL-6 and IL-8 is associated with scarless wound healing and a particularly low secretion of IL-6 and IL-8 is a specific feature of normal neonatal fibroblasts ([@b47-ijmm-40-05-1323],[@b48-ijmm-40-05-1323]). This data indicates that NCFs and OCCFs are influenced by the cleft status.

Expression profiles of fibroblasts isolated from the breast and face are distinct, this difference is maintained despite the orofacial cleft status and age of the donor. The facial fibroblasts originate from neural crest derived ectomesenchyme and, in comparison with fibroblasts of other origin and different nature, they are quite devoid of classical *HOX* gene expression ([@b49-ijmm-40-05-1323]--[@b51-ijmm-40-05-1323]). The present analysis demonstrated low activity of a subgroup of homeobox genes in facial fibroblasts when compared with fibroblasts from the breast tissue.

Based upon the analysis performed in the present study, the boundary between improved and almost scarless healing as referred to by aesthetic surgeons in cleft lip restoration ([@b52-ijmm-40-05-1323]) was not defined. However, the therapeutic window may be larger or site specific, as demonstrated by regeneration of the digit tip ([@b53-ijmm-40-05-1323]). The expression profiles of NCFs and OCCFs are practically identical and it must be noted that they differ from normal fibroblasts due to the high incidence of SMA-positive fibroblasts/myofibroblasts, typical of wound healing and stromal cancer-associated fibroblasts ([@b27-ijmm-40-05-1323]). Similar profiles of cleft palate and cancer have also been observed by others ([@b54-ijmm-40-05-1323]). Cancer-associated fibroblasts produce IL-6 and IL-8, which influence differentiation patterns of human keratinocytes to elements with low differentiation status ([@b38-ijmm-40-05-1323]). NCF/OCCF also produce these factors, and secrete TGF-β3 and exhibit a reduced quantity of TGF-βR2, which is associated with anti-fibrotic and anti-myofibroblast formation activity ([@b55-ijmm-40-05-1323]--[@b59-ijmm-40-05-1323]).

In conclusion, fibroblasts isolated from the cleft lip, as the most frequent congenital malformation of the face, reflect the disease status. Expression levels of nestin and changes in TGF-β signaling, which influence SMA expression levels in fibroblasts, participate in improved wound healing following neonatal cheiloplasty. Furthermore, the neural crest ectomesenchyme-derived fibroblasts significantly differ from fibroblasts isolated from the chest.
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![Comparison of nestin expression in adult, child and neonatal fibroblasts. Immunocytochemical detection of nestin-positive cells in (A) adults and (B) neonates, and (C) their percentage quantification in all studied fibroblasts. (D) Data from expression profiling. Potential statistical significance between tested types of fibroblasts was marked by use of line segments connecting tested cell types; ^\*^p\<0.05 indicates a statistically significant differences; ^\*\*^p\<0.05 indicates a statistically significant difference and a minimum of a 2-fold (δ\>2) change. Vim, vimentin; Nest, nestin; n.s., not significant.](IJMM-40-05-1323-g00){#f1-ijmm-40-05-1323}

![Expression of nestin in dermis samples obtained from (A) a child and (B) a neonate. Red signal detects fibroblasts positive for nestin. The nuclei of all cells are blue because they were counterstained with 4′,6-diamidino-2-phenylindole (DAPI).](IJMM-40-05-1323-g01){#f2-ijmm-40-05-1323}

![Detection of Nanog and Oct4 was performed by double staining immunocychemistry at single-cell level in neonatal fibroblasts that were negative for smooth muscle actin. Visualization of Nanog in (A) red tetramethylrhodamine channel, (B) Oct4 in green fluorescein isothiocyanate channel and (C) merged figure. (D and E) Data from expression profiles, where no significant differences were identified. Oct4, octamer-binding transcription factor 4.](IJMM-40-05-1323-g02){#f3-ijmm-40-05-1323}

![Expression levels of SMA in (A) adult breast and (B) neonatal fibroblasts as quantified by immunohistochemistry and (C) WB analysis of representative neonatal and adult fibroblasts. (D) Proportion of SMA-positive cells detected by immunocytochemistry. (E) *ACTA2* and (F) *ACTG2* gene activities are also demonstrated. Potential statistical significance between tested types of fibroblasts was marked by use of line segments connecting tested cell types; ^\*\*^p\<0.05 indicates a statistically significant difference and a minimum of a 2-fold (δ\>2) change. SMA, smooth muscle actin; WB, western blotting; ACTA2, actin α2, smooth muscle, aorta; ACTG2, actin γ2, smooth muscle, enteric; αTUB, α tubulin; mRNA, messenger RNA.](IJMM-40-05-1323-g03){#f4-ijmm-40-05-1323}

![Production of (A) IL-6 and (B) IL-8 to cultivation media measured by enzyme-linked immunosorbent assay (ELISA) compared with detection of (C) *IL-6* and (D) *IL-8* gene activity. Potential statistical significance between tested types of fibroblasts was marked by use of line segments connecting tested cell types; ^\*^p\<0.05 and ^\*\*^p\<0.05 indicates a statistically significant difference and a minimum of a 2-fold (δ\>2) change. IL, interleukin.](IJMM-40-05-1323-g04){#f5-ijmm-40-05-1323}

![Heat map demonstrating differences in the expression profiles of all of the investigated types of fibroblast.](IJMM-40-05-1323-g05){#f6-ijmm-40-05-1323}

![Heat map demonstrating the expression of HOX genes in all of the evaluated types of fibroblast.](IJMM-40-05-1323-g06){#f7-ijmm-40-05-1323}

![Detection of (A) *TGF-β2*, (B) *TGF-β3*, (C) *TGF-βR2* receptor, (D) *TGF-α* and (E) *SMAD3* gene activity in all of the tested types of fibroblast. Potential statistical significance between tested types of fibroblasts was marked by use of line segments connecting tested cell types; ^\*^p\<0.05 and ^\*\*^p\<0.05 indicates a statistically significant difference and a minimum of a 2-fold (δ\>2) change. TGF-β2, transforming growth factor-β2; TGF-βR2, transforming growth factor-β receptor 2; TGF-α, transforming growth factor-α; SMAD3, SMAD family member 3.](IJMM-40-05-1323-g07){#f8-ijmm-40-05-1323}

![Kyoto Encyclopedia of Genes and Genomes and TGF-β signaling pathway with changes between adult facial fibroblasts and neonate fibroblasts denoted by color code. TGF-β family member binds to the type II receptor and recruits type I, whereby type II receptor phosphorylates and activates type I. The type I receptor, in turn, phosphorylates receptor-activated Smads (R-Smads: Smad1, Smad2, Smad3, Smad5 and Smad8). Once phosphorylated, R-Smads associate with the co-mediator smad, smad4 and the heteromeric complex then translocates into the nucleus. In the nucleus, smad complexes activate specific genes via cooperative interactions with other DNA-binding and coactivator (or co-repressor) proteins. TGF-β, transforming growth factor-β; Smad, SMAD family member.](IJMM-40-05-1323-g08){#f9-ijmm-40-05-1323}

![Effect of TGF-β3 and TGF-β inhibitor on growth kinetics of neonate, child, and adult fibroblasts measured using IncuCyte. The time dependence of cell confluency is represented. The shadows determine the spread of the technical replicates. Note the insensitivity of neonatal cells to inhibition. TGF-β, transforming growth factor-β; DMEM, Dulbecco\'s modified Eagle\'s medium.](IJMM-40-05-1323-g09){#f10-ijmm-40-05-1323}

###### 

Antibodies used for immunohistochemical, immunocytochemical and western blot analysis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Primary antibody                                            Supplier (location)                                             Secondary antibody/fluorochrome                             Supplier (location)
  ----------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------------
  *Nestin/M* immunohistochemistry\                            Merck KGaA (Darmstadt, Germany)                                 Goat anti-mouse/TRITC 115-025-044; 1:30                     Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA)
  MAB5326; 1:200                                                                                                                                                                          

  *Nestin/P*\                                                 Sigma-Aldrich (Merck KGaA; Darmstadt, Germany)                  Swine anti-rabbit/FITC F0205; 1:30                          Dako (Agilent Technologies, Inc., Santa Clara, CA, USA)
  HPA007007; 1:200\                                                                                                                                                                       
  *Oct-4/P*\                                                                                                                                                                              
  P0056; 1:200                                                                                                                                                                            

  *CD45/M*\                                                   Dako (Agilent Technologies, Inc., Santa Clara, CA, USA)         Goat anti-mouse/TRITC T5393; 1:30                           Sigma-Aldrich (Merck KGaA; Darmstadt, Germany)
  C7556; 1:50\                                                                                                                                                                            
  *Vimentin/M*\                                                                                                                                                                           
  M0725; 1:50                                                                                                                                                                             

  *Smooth muscle actin/M*\                                                                                                                                                                
  M0851; 1:50                                                                                                                                                                             

  *Nanog/M*\                                                  R&D Systems, Inc. (Minneapolis, MN, USA)                        Donkey anti-goat/TRITC Sc-2094; 1:200                       Santa Cruz Biotechnology, Inc. (Dallas, TX, USA)
  AF1997; 1:15                                                                                                                                                                            

  Melan A/M\                                                  Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA)   Goat anti-mouse/TRITC 115-025-044; 1:30                     Sigma-Aldrich (Merck KGaA; Darmstadt, Germany)
  MA5-14168; 1:100\                                                                                                                                                                       
  *HMB-45 (anti-melanosome)/M* 081050 ready to use antibody                                                                                                                               

  *Wide spectrum cytokeratin/P*\                              Abcam (Cambridge, UK)                                           Swine anti-rabbit/FITC F0205; 1:30                          Dako (Agilent Technologies, Inc., Santa Clara, CA, USA)
  Ab9377; 1:100                                                                                                                                                                           

  *α-Tubulin (loading control)*\                              Sigma-Aldrich (Merck KGaA; Darmstadt, Germany)                  Goat anti-mouse/horseradish peroxidase Sc-516102; 1:2,000   Santa Cruz Biotechnology, Inc. (Dallas, TX, USA)
  T9026; 1:500                                                                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TRITC, tetramethylrhodamine; FITC, fluorescein isothiocyanate.
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